Relay Therapeutics Inc (RLAY)
NASDAQ:RLAY
Want to see RLAY full AI Analyst Report?
RLAY Stock Chart & Stats
$16.76
>-$0.01(-0.22%)
At close: 4:00 PM EST
$16.76
>-$0.01(-0.22%)
Day’s Range― - ―
52-Week Range$2.98 - $17.47
Previous CloseN/A
Volume391.09K
Average Volume (3M)3.94M
Market Cap
$3.01B
Enterprise Value$2.52B
Total Cash (Recent Filing)$642.07M
Total Debt (Recent Filing)$31.57M
Price to Earnings (P/E)―
Beta2.16
Next Earnings
Aug 06, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.57
Shares Outstanding191,586,170
10 Day Avg. Volume5,776,379
30 Day Avg. Volume3,942,204
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.56
Price to Sales (P/S)94.54
P/FCF Ratio-6.15
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue235.91
Enterprise Value/Gross Profit263.08
Enterprise Value/Ebitda-8.64
Forecast
1Y Price Target
$23.00Price Target Upside37.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-1.57
Revenue Forecast (FY)$11.13M
Bulls Say, Bears Say
Bulls Say
Computational-experimental Drug Discovery PlatformRelay’s integrated computational and experimental platform is a durable competitive asset: it improves understanding of protein motion, can raise hit-to-lead efficiency and de-risk candidate selection, and supports repeatable discovery across oncology and genetic-disease programs over multi-quarter timelines.
Promising Zovegalisib Phase 2 Data In Vascular AnomaliesRobust interim Phase 2 ReInspire signals (60% volumetric response, broad symptomatic improvement and tolerable safety) materially de-risk this rare-disease program, enabling expansion cohorts and pediatric dose-finding and increasing the chance this asset can become a sustainable revenue-driver beyond oncology.
Improved Near-term Liquidity From Large Equity RaiseThe underwritten offering that generated roughly $296.8M net proceeds lengthens funding runway, reducing immediate financing pressure and allowing Relay to advance Phase 2/3 programs and sponsor a planned Phase 3, which materially supports execution of multi-quarter development plans.
Bears Say
High And Persistent Cash BurnSustained negative operating and free cash flow (~-$213M TTM) means the business relies on external capital to fund R&D. If clinical timelines slip or milestones are delayed, recurring cash burn will force additional financing, raising execution risk and potential for further dilution over the medium term.
Deep Unprofitability And Eroding Equity BaseLarge cumulative losses (TTM net income ~ -$273M) and declining equity with ROE near -44% erode the company’s capital base. This reduces financial flexibility to absorb setbacks, weakens balance-sheet resilience over quarters, and constrains strategic options without successful clinical readouts.
Dilution Risk From Frequent Equity FinancingsRepeated and enlarging equity offerings (priced below prior close in the latest deal) signal structural reliance on shareholder funding. Continued issuance compresses existing ownership and per-share economics, making long-term returns contingent on successful clinical milestones and commercialization outcomes.
Relay Therapeutics News
RLAY FAQ
What was Relay Therapeutics Inc’s price range in the past 12 months?
Relay Therapeutics Inc lowest stock price was $2.98 and its highest was $17.47 in the past 12 months.
What is Relay Therapeutics Inc’s market cap?
Relay Therapeutics Inc’s market cap is $3.01B.
When is Relay Therapeutics Inc’s upcoming earnings report date?
Relay Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 63 days.
How were Relay Therapeutics Inc’s earnings last quarter?
Relay Therapeutics Inc released its earnings results on May 05, 2026. The company reported -$0.41 earnings per share for the quarter, missing the consensus estimate of -$0.363 by -$0.047.
Is Relay Therapeutics Inc overvalued?
According to Wall Street analysts Relay Therapeutics Inc’s price is currently Undervalued.
Does Relay Therapeutics Inc pay dividends?
Relay Therapeutics Inc does not currently pay dividends.
What is Relay Therapeutics Inc’s EPS estimate?
Relay Therapeutics Inc’s EPS estimate is -0.4.
How many shares outstanding does Relay Therapeutics Inc have?
Relay Therapeutics Inc has 191,586,170 shares outstanding.
What happened to Relay Therapeutics Inc’s price movement after its last earnings report?
Relay Therapeutics Inc reported an EPS of -$0.41 in its last earnings report, missing expectations of -$0.363. Following the earnings report the stock price went down -0.615%.
Which hedge fund is a major shareholder of Relay Therapeutics Inc?
Currently, no hedge funds are holding shares in RLAY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Relay Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.00 (37.23% Upside)
$23.00 (37.23% Upside)
Blogger Sentiment
Bullish
RLAY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 7.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $47.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.7%
Last 30 Days ▲ 14.2%
Last 30 Days ▲ 14.2%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
393.71%
12-Months-Change
Fundamentals
Return on Equity
-43.94%
Trailing 12-Months
Asset Growth
-12.48%
Trailing 12-Months
Company Description
Relay Therapeutics Inc
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
RLAY Stock 12 Month Forecast
Average Price Target
$23.00
▲(37.23% Upside)
Technical Analysis
Ownership Overview
2.16% Insiders
9.38% Mutual Funds
59.31% Other Institutional Investors
16.26% Public Companies and Individual Investors